Departments of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Departments of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Br J Surg. 2017 Feb;104(3):267-277. doi: 10.1002/bjs.10415. Epub 2017 Jan 4.
The clinical significance of abnormally high levels of carbohydrate antigen (CA) 19-9 after resection of biliary tract cancer (BTC) is not well established. The aim of this study was to determine the prognostic value of CA19-9 normalization in patients undergoing resection of BTC with curative intent.
Patients with BTC undergoing resection with curative intent (1996-2015) were divided into those with normal preoperative CA19-9 level (normal CA19-9 group), those with an abnormally high preoperative CA19-9 level (over 37 units/ml) and normal postoperative CA19-9 level (normalization group), and those with an abnormally high preoperative CA19-9 level and abnormally high postoperative CA19-9 level (non-normalization group). Overall survival (OS) was analysed and predictors of OS were determined.
The normal CA19-9 group (180 patients) and normalization group (74) had better OS than the non-normalization group (58) (3-year OS rate 70·4, 73 and 31 per cent respectively; both P < 0·001). The normal CA19-9 and normalization groups had equivalent OS (P = 0·880). On multivariable analysis, factors associated with worse OS were lymph node metastases (hazard ratio (HR) 1·78; P = 0·014) and abnormally high postoperative CA19-9 level (HR 3·16; P < 0·001). In the normalization group, OS did not differ after R0 versus R1 resection (3-year OS rate 69 versus 62 per cent respectively; P = 0·372); in the non-normalization group, patients with R1 resection had worse OS (3-year OS rate 36 and 20 per cent for R0 and R1 respectively; P = 0·032).
Non-normalization of CA19-9 level after resection of BTC with curative intent was associated with worse OS. R1 resection was associated with a particularly poor prognosis when CA19-9 levels did not normalize.
胆道癌(BTC)切除术后异常升高的碳水化合物抗原(CA)19-9 的临床意义尚未明确。本研究旨在确定具有治愈意图的 BTC 切除术后 CA19-9 正常化患者的预后价值。
对 1996 年至 2015 年间接受治愈性切除的 BTC 患者进行分组,分为术前 CA19-9 水平正常(正常 CA19-9 组)、术前 CA19-9 水平异常升高(>37 单位/ml)且术后 CA19-9 水平正常(正常化组)和术前 CA19-9 水平异常升高且术后 CA19-9 水平异常升高(未正常化组)。分析总生存期(OS)并确定 OS 的预测因素。
正常 CA19-9 组(180 例)和正常化组(74 例)的 OS 明显优于未正常化组(58 例)(3 年 OS 率分别为 70.4%、73%和 31%;均 P<0.001)。正常 CA19-9 组和正常化组的 OS 无差异(P=0.880)。多变量分析显示,与较差 OS 相关的因素是淋巴结转移(风险比(HR)1.78;P=0.014)和术后 CA19-9 水平异常升高(HR 3.16;P<0.001)。在正常化组中,RO 与 R1 切除术后 OS 无差异(3 年 OS 率分别为 69%和 62%;P=0.372);在未正常化组中,R1 切除术后 OS 较差(3 年 OS 率分别为 R0 和 R1 组的 36%和 20%;P=0.032)。
BTC 切除术后 CA19-9 水平未正常化与 OS 较差相关。当 CA19-9 水平未正常化时,R1 切除与预后尤其差相关。